Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    REGENXBIO Inc.

    NASDAQ: RGNX · Real-Time Price · USD
    7.84
    -0.59 (-7.00%)
    At close: Jun 23, 2025, 3:59 PM
    8.08
    3.06%
    After-hours: Jun 23, 2025, 07:27 PM EDT
    -7.00%
    Bid 7.8
    Market Cap 395.05M
    Revenue (ttm) 156.72M
    Net Income (ttm) -157.69M
    EPS (ttm) -3.09
    PE Ratio (ttm) -2.54
    Forward PE -5.58
    Analyst Buy
    Ask 8.08
    Volume 709,555
    Avg. Volume (20D) 1,144,064
    Open 8.36
    Previous Close 8.43
    Day's Range 7.82 - 8.45
    52-Week Range 5.04 - 15.36
    Beta 1.09

    About RGNX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RGNX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for RGNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    REGENXBIO Inc. is scheduled to release its earnings on Jul 31, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    -17.06%
    Regenxbio shares are trading lower after the compa... Unlock content with Pro Subscription
    1 month ago
    +2.63%
    RGNX stock has given up its prior gain. Regenxbio shares were trading higher following Q1 financial results and after the company announced FDA acceptance and priority review of BLA for RGX-121.
    news image

    2 weeks ago · seekingalpha.com

    Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

    REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA d...

    news image

    2 weeks ago · benzinga.com

    Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

    RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.

    news image

    1 month ago · seekingalpha.com

    REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

    REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & CEO Steve Pakola - Chie...

    news image

    1 month ago · zacks.com

    Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

    Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago.

    news image

    1 month ago · zacks.com

    Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · seekingalpha.com

    5 Reasons To Buy Regenxbio Right Now

    Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, wit...

    Add to Watchlist